Xechem Signs Paclitaxel Alliance With Czech Firm

Xechem International, Inc. and Lachema a.s., a manufacturer and marketer of pharmaceuticals based in the Czech Republic, have signed a strategic alliance agreement for the manufacture and marketing of paclitaxel in Central and East European Countries.

Under the terms of the agreement, Lachema obtains exclusive rights to register and sell injectable paclitaxel in 19 Central and Eastern European countries and non-exclusive rights in the Federal Republic of Germany and Russia. Paclitaxel is commonly known as Taxol (a registered trademark of Bristol-Myers Squibb). Lachema is also granted the right to manufacture injectable paclitaxel vials from paclitaxel purchased from Xechem.

Xechem obtains the exclusive right to register and sell Lachema's anticancer and antiviral preparations containing methotrexate and acyclovir in the United States, Canada, Mexico, five South American countries and the Scandinavian area.

For more information: Dr. Ramesh C. Pandey, president and CEO, Xechem International, Inc. 100 Jersey Ave, Building B, Suite 310, New Brunswick, NJ 08901. Telephone: 732-247-3300. Fax: 732-247-4090.